In a conversation with BioCentury, AstraZeneca’s Menelas Pangalos highlighted the technologies the pharma thinks could be difference-makers in the pandemic, and the external resources required to reduce them to practice. In the past month, AstraZeneca...

In Zai’s latest deal giving it local rights to a therapeutic developed in the West, the Shanghai-based biotech has partnered with Regeneron for REGN1979, a bispecific antibody that is in Phase II testing to treat...

With Prime Minister Boris Johnson now in the ICU, the urgency for answers to COVID-19 takes on a new dimension in the U.K., and the spotlight on its biopharmas to respond with countermeasures beyond physical...

A $250 million investment by GlaxoSmithKline will put the clinical trial expertise and regulatory acumen of one of the leading anti-infective drug companies behind Vir’s effort to bring an antibody therapy to fight against COVID-19,...

COVID-19 may be putting the brakes on a broad swath of biopharma deals, but it has also triggered a host of partnerships for coronavirus countermeasures, pushing vaccine deals to their highest numbers in years. Many...

BARDA’s latest push into plasma-based COVID-19 therapies includes an expanded access program for convalescent plasma and funding for Emergent’s hyperimmune program. To combat the pandemic, a pair of companies began rolling out tests, while GSK...

CureVac AG said Deputy Chairman Jean Stéphenne will become chairman. He is the former president and chairman of the biologicals unit of GlaxoSmithKline plc (LSE:GSK; NYSE:GSK). It's another management change for the biotech as it...

For its first pharma partnership, U.K.-based Sitryx is granting Lilly rights to its two most advanced immunometabolism programs in exchange for upfront cash and an equity investment totaling $60 million -- twice the amount of...

Global alliances among public, private and non-profit entities to counter COVID-19 continue to gather steam, with one of the latest alliances comprising over a dozen life sciences companies and the Gates Foundation. Novartis AG (NYSE:NVS;...

Epizyme Inc. (NASDAQ:EPZM) hired Jeffery Kutok as CSO. He was EVP and CSO of Infinity Pharmaceuticals Inc. (NASDAQ:INFI). Kutok joins the epigenetics company in the wake of its first FDA approval, for Tazverik tazemetostat to...